9.13.19
17 min. read

The Pear Therapeutics Report

In this article:

In this 4,500-word report, E&O digs into the strategic moves, challenges, and successes that the Pear Therapeutics executive team has navigated since its founding five years ago. The report covers dozens of Pear’s therapeutic areas of interest; financial details from licensing agreements the company has forged with academic researchers; why it acquired a small tech startup in its early years; its failed direct-to-consumer products and more.

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Fresh from vacation, ex-McKinsey analyst and then-venture capitalist Corey McCann M.D. Ph.D. stepped up to the mic at the first-ever NeuroGaming conference in 2013 and asked a question. Well, three actually: "Who's going to pay for this? How much? And why?"

In his retelling of the episode, the room fell silent. The panelists, who were all dabbling in healthcare applications for neurogames, had no good answers.

A year later, while still working as a principal at MPM Capital, McCann returned to the conference, sat on a similar panel, and introduced himself as the CEO of a new startup named Pear Therapeutics. Software plus drugs were better than either alone, he argued. [cited tooltip='Stephen Kennedy Smith, a scion of the Kennedy family, also helped incubate Pear via his holding company New Frontier Bio.']Pear Therapeutics was born[/cited].

Pear Therapeutics has come a long way in the

×

Recent Articles